Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Announces Partnership with NIH Consortium

Published: Tuesday, October 16, 2012
Last Updated: Tuesday, October 16, 2012
Bookmark and Share
Adds more than 140 peer-validated neuroscience-specific monoclonal antibodies to portfolio.

Merck Millipore has announced that Merck Millipore has entered into an agreement with an academic consortium funded by the NIH, to distribute more than 140 peer-validated neuroscience-specific monoclonal antibodies through its worldwide network.

This set of antibodies has been specifically requested by academic researchers for key targets in neuroscience research.

The antibodies have been submitted and vetted through a formal process, led by academicians, and have been determined to be valuable and worthy of development in light of today's neuroscience research priorities.

These key targets in neurodevelopment, metabolism, oxidative stress, synaptic function, neurodegeneration and disease have been tested in multiple species, including genetic knockout mice.

In addition, the antibodies have been independently peer-reviewed and research validated prior to being made available through Merck Millipore.

"Merck Millipore's objective is to help our customers advance the study of neuroscience," notes John Sweeney, Executive Vice President, Merck Millipore Bioscience Division.

Sweeney continued, "We are excited about this partnership with the NIH consortium, one of the largest sources of medical research funding in the world. This partnership will enable us to provide access to this novel range of neuroscience antibodies in addition to others, allowing us to provide cutting edge tools for researchers focused on metabolism, oxidative stress, synaptic function, neurodegeneration and more."

Merck Millipore is currently one of the top antibody manufacturers worldwide, with the majority of antibodies licensed and manufactured in California.

A significant number of Merck Millipore's antibody portfolio and technical expertise includes antibodies and research staff from Chemicon®, Upstate®, Linco® and Calbiochem®, which were acquired by the company over the past several years.

With its primary focus on quality and stringent validation, Merck Millipore's antibodies are backed by its commitment to quality and a unique performance guarantee.

In addition to developing and testing a wide range of antibodies, Merck Millipore has research and development teams dedicated to expanding its significant portfolio of immunotechnologies including its Multiplex, Elisas, and other cell-based assays, as well as novel flow cytometry, guava easycyte®, Amnis® and Muse® products for cell analysis and imaging.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Scientific News
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Antibodies Block Norovirus’ Entrance into Cells
Scientists have uncovered a mechanism in the human body that targets and successfully blocks noroviruses.
Probe Detects Histone Modifications in Cells
Scientists have developed an antibody probe that can be used to monitor the dynamics of histone modification.
Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
Researcher have discovered that harm caused by pathogens in the intestinal tract benefit from immune system response to damaged intestinal lining.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!